Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.67 |
| ▸ | CETP | P11597 | 13/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.58 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1054596 | 1.00 | PTGDR2 (0.67) | PTGDR2CETPTBXA2RPTGDRNR1I2 | |
| SCHEMBL1060483 | 0.91 | CETP (0.61) | PTGDR2CETPNR1I2KCNH2 | |
| SCHEMBL13703997 | 0.87 | PTGDR2 (0.67) | PTGDR2CETPTBXA2RPTGDRNR1I2 | |
| SCHEMBL1060087 | 0.85 | PTGDR2 (0.62) | PTGDR2CETPTBXA2RPTGDR | |
| SCHEMBL12931902 | 0.84 | PTGDR2 (0.48) | PTGDR2CETPTBXA2RPTGDRNR1I2 | |
| SCHEMBL12931913 | 0.84 | PTGDR2 (0.48) | PTGDR2CETPTBXA2RPTGDRNR1I2 | |
| SCHEMBL531804 | 0.83 | CETP (0.61) | CETPNR1I2 | |
| SCHEMBL4214900 | 0.83 | CETP (0.61) | CETPNR1I2 | |
| SCHEMBL4214903 | 0.83 | CETP (0.61) | CETPNR1I2 | |
| SCHEMBL1058225 | 0.82 | PTGDR2 (0.52) | PTGDR2CETPTBXA2RPTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497381-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-07-30 | — | — | US | disclosed |
| US-8497381-B2 | Antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110021573-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021573-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| WO-2009108720-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021573-A1 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885CETP 3640/4885TBXA2R 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.